Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

2.

Chronic pain and poor sleep are troublesome bed partners.

3.

In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.

4.

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?

5.

combating racial discrimination in next-generation breast cancer screening.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot